This message was sent to ##Email##
|
| January 25, 2017 |
| |  | | |
|
|
|
| |
Medical Daily
Doctors may be able to better tailor cervical cancer treatments to different patients with the discovery of a new subtype of the disease.
Although almost all cervical cancers can be traced back to a longlasting infection of human papillomavirus, a study in the journal Oncotarget found that in some tumors containing DNA of that virus, the HPV was actually inactive — the cancers were triggered by HPV, but the virus did not direct the cancer’s progression.
READ MORE
ASCT
The winner will receive $150 cash! Your design and slogan must be submitted by February 1, 2017. Click here for contest rules and how to submit your design. Learn more about NCD Day and get inspiration from past winners here.
2016 winner, Cristina Duluc, Charlotte, North Carolina
| Date |
Event |
Location |
More information |
February 15, 2017
2 p.m. EST
|
The Paris System of Reporting Urinary Cytology |
Your PC |
 Güliz A. Barkan, M.D., FIAC
Associate Professor of Pathology and Urology
Loyola University Healthcare System>
Maywood, Illinois
More info |
Register
|
March 15, 2017
2 p.m. EST
|
Evolution in Action: Cytotechnologists and USFNA |
Your PC |
 Adele O. Kraft, MD
Assistant Professor
Director, Cytopathology
Department of Pathology
 Mary Ellen Clark
Cytotechnologist
Virginia Commonwealth University Health System
Richmond, Virginia
More info |
Register
|
Available for 6 months after subscribing |
Quality Assessment Center (QAC) Cell Blocks Basics Workbench
|
Your PC |
Details |
Available for 6 months after subscribing |
Quality Assessment Center (QAC)
Document Control for Cytopathology Workbench
|
Your PC |
Details |
Available for 6 months after subscribing |
Quality Assessment Center (QAC)
The LEAN Cytopathology Laboratory Workbench
|
Your PC |
Details |
Medscape (free login required)
In a recent international clinical trial, Iversen and colleagues evaluated whether a two-dose HPV vaccine schedule for boys and girls aged 9-14 years could produce an immune response similar to that of a three-dose series given to young adult women (16-26 years). The data were collected from 2013 through 2015 at 52 ambulatory sites in 15 different countries. The children were healthy and had no sexual activity before enrollment.
READ MORE
 |
|
The Cyto-Tek® 2500 offers excellent
preservation of cellular structure and consistently delivers a high rate of
cellular recovery. With its patented paced acceleration feature, the instrument
automatically increases and decreases the rotational velocity based on the selected
speed, which protects fragile cells and results in higher cellular yield.
|
|
Fox News
The first national estimate suggests that nearly half of U.S. men have genital infections caused by a sexually transmitted virus and that 1 in 4 has strains linked with several cancers.
Most human papillomavirus infections cause no symptoms and most disappear without treatment. And most adults will get an HPV infection at some point in their lives.
But high-risk HPV can cause cancer in the mouth and upper throat, cervical cancer in women and other cancers. Less harmful strains can cause genital warts.
READ MORE
Cancer Network
The impetus is that we are still seeing women present with advanced cervical cancer, recurrent cervical cancer, and even dying from cervical cancer, which is ultimately a preventable disease. Worldwide, the burden on young women is quite high with about half a million cases per year.
READ MORE
Research and Markets via Business Wire
Research and Markets has announced the addition of the "Global Cervical Cancer Epidemiology and Patient Flow Analysis — 2017" report to their offering. The results of the Cervical Cancer patients study are announced in this new report. The report provides insights into Cervical Cancer epidemiology, Cervical Cancer diagnosed patients, and Cervical Cancer treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Cervical Cancer derived from epidemiological analysis, percentage of patients diagnosed with Cervical Cancer, and percentage of patients treated with a therapy.
READ MORE
Greenville News
Researchers from the University of South Carolina say they have found a new subtype of cervical cancer that may not respond to conventional treatment.
The new strain affects 8 percent of patients, according to the team led by Carolyn Banister, assistant research professor, and Phillip Buckhaults, associate professor, both in the Department of Drug Discovery and Biomedical Sciences at the USC College of Pharmacy. Buckhaults is also director of the Cancer Genetics Lab.
READ MORE
Cervical Cancer News
Puma Biotechnology has added more cervical cancer patients to its Phase 2 trial of PB272 (neratinib), a therapy that can be used alone or with other therapies to treat patients with solid tumors and an activating HER2 mutation.
The company made the decision after preliminary data indicated that the therapy helped those with cervical cancer. The fourth cohort of the SUMMIT trial includes 18 more patients with HER2-mutant cervical cancer.
READ MORE
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
